Loading...
Market
What will be the FDA's decision on Unicycive's Oxylanthanum Carbonate by September 4, 2025?
2
Resolution / Starting Odds
Approved • 25%
Rejected • 25%
Request for additional trials • 25%
Request for additional data • 25%
FDA official announcements and Unicycive Therapeutics press releases
Story
Unicycive ($UNCY) Submits NDA for Oxylanthanum Carbonate, Awaits FDA Acceptance
Sep 4, 2024, 09:04 AM
Unicycive Therapeutics ($UNCY) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The submission follows the 505(b)(2) regulatory pathway. Unicycive has partnered with Shilpa Medicare to provide end-to-end contract development and manufacturing organization (CDMO) services. The next steps include FDA acceptance and setting a PDUFA date.
View original story
Similar markets
Approved without conditions • 25%
Approved with conditions • 25%
Approval delayed • 25%
Not approved • 25%
Approval • 33%
Rejection • 33%
Request for more data • 34%
Another cancer therapy • 25%
A non-cancer therapy • 25%
No new approvals • 25%
Other • 25%
Yes • 50%
No • 50%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Clinical hold • 25%
No action • 25%
Request for additional data • 25%
Other • 25%
Approved • 33%
Rejected • 33%
Request for more data • 34%
No action taken • 25%
Warning issued • 25%
Fine imposed • 25%
Other sanctions • 25%